Aytu Biopharma, Inc.
AYTU
$1.27
$0.0050.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.48% | -6.98% | -41.51% | -20.85% | -28.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.48% | -6.98% | -41.51% | -20.85% | -28.66% |
| Cost of Revenue | 31.12% | -3.98% | -56.11% | -36.94% | -53.87% |
| Gross Profit | -26.14% | -8.08% | -31.93% | -8.24% | -15.56% |
| SG&A Expenses | -2.96% | -12.93% | -21.33% | -39.99% | -46.08% |
| Depreciation & Amortization | 0.33% | -0.32% | 9.04% | 8.76% | -23.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.39% | -10.51% | -32.76% | -36.88% | -48.80% |
| Operating Income | -112.02% | 83.16% | -128.44% | 76.11% | 175.03% |
| Income Before Tax | -72.69% | 120.05% | -59.63% | 63.31% | 120.90% |
| Income Tax Expenses | -136.28% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.43% | 114.63% | -87.91% | 59.90% | 109.25% |
| Earnings from Discontinued Operations | 114.66% | 158.89% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 458.18% | 118.15% | -87.91% | 59.90% | 96.71% |
| EBIT | -112.02% | 83.16% | -128.44% | 76.11% | 175.03% |
| EBITDA | -80.53% | 31.25% | -76.75% | 95.76% | 348.47% |
| EPS Basic | 422.06% | 116.40% | -38.57% | 73.00% | 98.15% |
| Normalized Basic EPS | 9.27% | 127.58% | -90.58% | 79.65% | 119.63% |
| EPS Diluted | -523.75% | 89.33% | -38.57% | 73.00% | 98.04% |
| Normalized Diluted EPS | -21.07% | 118.39% | -90.58% | 79.65% | 119.63% |
| Average Basic Shares Outstanding | 11.14% | 10.69% | 35.61% | 48.48% | 77.40% |
| Average Diluted Shares Outstanding | 53.78% | 65.99% | 35.61% | 48.48% | 77.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
